Kristian Reich Sells Shares of MoonLake Immunotherapeutics
Kristian Reich, Chief Scientific Officer at MoonLake, sold 50,000 shares for $935,000.
Key Points
- Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, sold 50,000 shares on June 16, 2026, for $935,000.
- MoonLake Immunotherapeutics trades on NasdaqCM under the ticker MLTX, with a market cap of approximately $1.4 billion and a 52-week range of $5.95 to $62.75.
- Analysts maintain a positive outlook with firms like Needham and HC Wainwright & Co. rating it a 'buy', setting price targets as high as $45.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Kristian Reich, the Chief Scientific Officer of MoonLake Immunotherapeutics, recently sold 50,000 shares of the company. The transaction took place on June 16, 2026, at an average price of $18.70 per share, totaling $935,000. This sale was part of a planned transaction.
Insider Buying and Selling at MoonLake Immunotherapeutics
Kristian Reich has been actively selling shares in recent days, with transactions on June 15 and June 17 as well. On June 15, he sold another 50,000 shares at $18.89 each, and on June 17, he sold 50,000 shares at $19.43 each. All these sales were planned. Additionally, Matthias Bodenstedt, the Chief Financial Officer, sold shares in May and April, and CEO Dr. Jorge Santos da Silva sold shares in April.
Other Institutional Activity in MoonLake Immunotherapeutics
Several institutional investors have adjusted their positions in MoonLake Immunotherapeutics. BVF Inc/IL reduced its holdings by 3,750,000 shares, ending with 16,001,284 shares valued at about $298 million. In contrast, Deep Track Capital, LP increased its stake by 1,798,792 shares, bringing its total to 6,408,863 shares worth approximately $119 million. Cormorant Asset Management, LP added 125,000 shares, achieving a total of 4,480,433 shares valued at $83.5 million. Janus Henderson Group PLC also increased its position significantly, adding 1,355,640 shares to reach a total of 3,451,628 shares worth $64.3 million.
MoonLake Immunotherapeutics Stock Up 28.0%
Shares of MoonLake Immunotherapeutics, trading on NasdaqCM under the ticker MLTX, were recently priced at $18.98. The company has a market cap of about $1.4 billion. It is a clinical-stage biotechnology firm with a beta of 1.036, indicating moderate volatility. The stock's 52-week range is between $5.95 and $62.75. It has a 50-day moving average of $17.84 and a 200-day moving average of $19.20. MoonLake's current ratio is 8.601, and its debt-to-equity ratio is 39.682, reflecting its financial health.
$MLTX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have shown a positive outlook for MoonLake Immunotherapeutics. On May 12, 2026, Needham maintained its 'buy' rating with a $30 price target. HC Wainwright & Co. also maintained a 'buy' rating with a $45 target on May 11, 2026. The consensus recommendation is 'buy', with a mean price target of $27.62 based on 13 analyst opinions.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a biotechnology company focused on developing treatments for inflammatory skin and joint diseases. Headquartered in Zug, Switzerland, the company is led by CEO Dr. Jorge Santos da Silva. MoonLake is working on a promising treatment called Sonelokimab, targeting diseases like hidradenitis suppurativa and psoriasis. Founded in 2021, the company employs around 130 people.
Bottom Line
Kristian Reich's recent planned sales of MoonLake Immunotherapeutics shares are part of ongoing insider transactions. The company's stock is closely watched due to its innovative treatments and the volatility seen in its trading range. Investors and analysts keep an eye on such insider activity and institutional movements, as they can provide insights into the company's prospects. Remember, 13F filings and insider transactions reflect past actions and may not indicate current positions.
Get MoonLake Immunotherapeutics alerts
New 13F filings, insider trades, and analyst moves on $MLTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.